E
ReShape Lifesciences Inc. RSLS
$0.6165 -$0.0185-2.91%
Recommendation
Sell
Prev Close
$0.635
Volume
140,788
Avg Vol (90D)
790,370
Market Cap
$2.10M
Dividend & Yield
--
52-Week Range
$0.626 - $29.00
P/E (TTM)
--
EPS (TTM)
-$18.59
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E+
Very Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Very Weak
Dividend Index
--
Headlines
ReShape Lifesciences Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
3/10/2025 - Globe Newswire
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
3/10/2025 - Stocktwits News Feed
ReShape Lifesciences signs distribution agreement with Liaison Medical
2/25/2025 - The Fly
ReShape Lifesciences Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band 2.0 FLEX
2/25/2025 - Globe Newswire
ReShape Lifesciences Announces Securities Purchase Agreement
2/20/2025 - TipRanks Financial Blog
ReShape Lifesciences 2.6M share Secondary priced at $2.33
2/18/2025 - The Fly
ReShape Lifesciences prices $6M public offering
2/17/2025 - SeekingAlpha.com: All News
ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering
2/16/2025 - Globe Newswire
ReShape Lifesciences receives international patent in Israel for its proprietary diabetes neuromodulation technology; shares rise
2/3/2025 - Seeking Alpha - Healthcare
ReShape Lifesciences granted key IP in Israel
2/3/2025 - The Fly
ReShape Lifesciences Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
2/3/2025 - Globe Newswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LBRDA, OMIC, NEUE, RSLS on Behalf of Shareholders
1/28/2025 - PR Newswire
ReShape Lifesciences files to sell common stock, no amount given
1/21/2025 - TipRanks Financial Blog
ReShape Lifesciences files to sell common stock, no amount given
1/21/2025 - The Fly
ReShape Lifesciences updates on merger with Vyome Therapeutics
1/13/2025 - The Fly
ReShape Lifesciences updates on merger with Vyome Therapeutics
1/13/2025 - The Fly
ReShape Lifesciences Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
1/13/2025 - Globe Newswire
ReShape Lifesciences files to sell 2.11M shares of common stock for holders
12/20/2024 - The Fly
ReShape Lifesciences Announces Merger and Asset Sale Plans
12/11/2024 - TipRanks Financial Blog
Reshape Lifesciences Inc (RSLS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
11/15/2024 - GuruFocus
Q3 2024 ReShape Lifesciences Inc Earnings Call Transcript
11/15/2024 - GuruFocus
ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript
11/15/2024 - SeekingAlpha
ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript
11/15/2024 - Seeking Alpha: Transcripts
ReShape Lifesciences Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
11/14/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$8.18M
EBITDA (TTM)
-$7.90M
EBIT (TTM)
-$7.92M
Net Income (TTM)
-$7.07M
Balance Sheet
Total Assets (Q)
$5.62M
Total Debt (Q)
$191.00K
Total Liabilities (Q)
$4.13M
Book Value Per Share (Q)
$2.11
Cash Flow
Cash from Operations (TTM)
-$6.20M
Cash from Investing (TTM)
$0.00
Cash from Financing (TTM)
$5.49M
Net Change in Cash (TTM)
-$706.00K
Filings
Filing Date
Thursday, November 14, 2024
Period Date
Monday, September 30, 2024
Next Filing
Beginning of April (est)
Price History
Loading...
Beta
1.68
7-Day Total Return
-37.73%
30-Day Total Return
-83.65%
60-Day Total Return
-86.94%
90-Day Total Return
-89.09%
Year to Date Total Return
-86.48%
1-Year Total Return
-93.71%
2-Year Total Return
-99.66%
3-Year Total Return
-99.98%
5-Year Total Return
-100.00%
52-week Low
Mar 13, 2025 - $0.626
52-week High
May 29, 2024 - $29.00
Valuation
Market Cap
$2.10M - Nano Cap
Enterprise Value
$1.55M
Price/Sales (TTM)
0.04
Price/Book (Q)
0.30
Dividends and Shares
Shares Outstanding
508.90K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.reshapelifesciences.com
Phone Number
949 429 6680
Address
18 Technology Drive
Irvine, CA 92618
Country
United States
Year Founded
2002
Business Description
Sector
Health Care
Industry
Health Care Equipment and Services
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product... more
NASDAQ 03/14/2025 12:38PM Eastern Quotes delayed
Weiss Ratings